Article
- The EMBO Journal (2002) 21, 6771 - 6780
- doi:10.1093/emboj/cdf684
Subject Categories:
PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumour modifier protein
Mary T. Scott1, Angela Ingram1 and Kathryn L. Ball1
- Cancer Research UK Laboratories, University of Dundee Medical School, Dundee DD1 9SY, UK
Correspondence to:
Kathryn L. Ball, E-mail: k.l.ball@dundee.ac.uk
Received 26 March 2002; Accepted 30 October 2002; Revised 14 October 2002
Abstract
p21WAF1/CIP1 contributes to positive and negative growth control on multiple levels. We previously mapped phosphorylation sites within the C-terminal domain of p21 that regulate proliferating cell nucear antigen binding. In the current study, a kinase has been fractionated from mammalian cells that stoichiometrically phosphorylates p21 at the Ser146 site, and the enzyme has been identified as an insulin-responsive atypical protein kinase C (aPKC). Expression of PKC
or activation of the endogenous kinase by 3-phosphoinositide dependent protein kinase-1 (PDK1) decreased the half-life of p21. Conversely, dnPKC
or dnPDK1 increased p21 protein half-life, and a PDK1-dependent increase in the rate of p21 degradation was mediated by aPKC. Insulin stimulation gave a biphasic response with a rapid transient decrease in p21 protein levels during the initial signalling phase that was dependent on phosphatidylinositol 3- kinase, PKC and proteasome activity. Thus, aPKC provides a physiological signal for the degradation of p21. The rapid degradation of p21 protein during the signalling phase of insulin stimulation identifies a novel link between energy metabolism and a key modulator of cell cycle progression.
Keywords:
- aPKC,
- degradation,
- insulin,
- p21,
- phosphorylation



